What a humanitarian device exemption actually requires

A Humanitarian Device Exemption looks, from a distance, like a shortcut to market. It isn’t. It trades one evidentiary bar for a different set of ongoing obligations, and most of the trouble people get into with HDEs comes from treating it as the easy pathway rather than the differently-hard one.

What “probable benefit” actually means

A traditional PMA asks FDA to find reasonable assurance that a device is both safe and effective, built on evidence sized to detect that effect reliably. An HDE asks something narrower: that the probable benefit to health outweighs the risk of illness or injury, given the absence of a population large enough to study the traditional way. That is still a real, substantive finding — FDA has to be convinced the device is safe and that the available evidence supports a reasonable expectation of benefit — but it is not the same finding a cleared or approved device carries, and treating an HDE-approved device as though it cleared that higher bar misstates what FDA actually decided. The contrast shows up clearly against a PMA’s own summary of safety and effectiveness data, which documents a different kind of evidence entirely.

The IRB requirement nobody budgets for

Because an HDE device hasn’t cleared the effectiveness bar, FDA leans on local institutional review board oversight to do work the evidence itself can’t: a hospital’s IRB generally has to approve use of the device before it’s used there, and keep reviewing that use going forward, with a narrow emergency-use exception. For a sponsor, that means every new site that wants to use the device is a new IRB relationship to manage, not a one-time regulatory submission — a real commercial and operational cost that a PMA or 510(k) clearance doesn’t carry, and one that’s easy to under-scope if you’re comparing the HDE pathway only on how it looks on paper next to a designation like orphan drug status rather than on what it actually requires day to day.

What actually forces the HDE route

In practice, nobody chooses an HDE because it looks easier. It gets chosen because a traditional trial sized to show effectiveness isn’t realistic against a population this small, and the alternative is no pathway to market at all for a device that may genuinely help patients who have nothing else. That is also why the profit rules attached to HDEs have been revisited by Congress more than once — lawmakers have tried, at different points, to make the pathway more commercially viable for exactly the populations it’s meant to serve, which is one more reason to check current guidance rather than rely on what the rule used to say.

None of this makes the HDE pathway a lesser one — it makes it a different trade, built for a situation a standard premarket pathway genuinely can’t serve. Reading it as a shortcut is the mistake; reading it as its own standard, with its own ongoing obligations, is what actually prepares you to work with one, in much the same way a Breakthrough Device designation changes FDA’s attention without changing the evidence it ultimately requires.